AMYL-00y

AMYL-00y is a preclinical-stage monoclonal antibody being developed by Amyl Therapeutics for the treatment of various neurodegenerative diseases. It is part of the company's Pan-Amyloid Immunotherapy (PAI) platform, which utilizes antibodies designed to recognize and bind to the cross-β sheet conformation common to multiple types of toxic protein aggregates, such as amyloid-β, tau, and α-synuclein. Unlike traditional antibodies that target a single protein species, AMYL-00y is engineered to provide a broader therapeutic effect by targeting the shared structural fold of amyloid fibrils. The candidate is optimized for enhanced brain penetration and safety, specifically aiming to avoid risks like amyloid-related imaging abnormalities (ARIA). While its specific molecular targets remain undisclosed, it is positioned for the treatment of neurodegenerative disorders beyond the primary focuses of Alzheimer's and Parkinson's diseases.